News
CMPS
9.65
-2.62%
-0.26
Weekly Report: what happened at CMPS last week (0504-0508)?
Weekly Report · 1d ago
Earnings week ahead: BABA, CSCO, PLUG, AMAT, JD, and more
Seeking Alpha · 1d ago
A Look At COMPASS Pathways (CMPS) Valuation After Phase 3 COMP005 Success In Treatment Resistant Depression
Simply Wall St · 2d ago
EXE, IP, ESPR, CMPS, TNXP Trending With Analysts
TipRanks · 3d ago
'Health Officials Close To U.S. Secretary Kennedy Explored Ban Of Some Widely Used Antidepressants' - Reuters Exclusive
Benzinga · 3d ago
Psychedelic: Jefferies initiates Compass Pathways with a Buy rating
TipRanks · 4d ago
Compass Pathways to report Q1 results, hosts conference call
PUBT · 6d ago
Compass Pathways grants 125,335 inducement stock options at $9.01 per share
PUBT · 6d ago
Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026
Barchart · 6d ago
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 6d ago
Health Rounds: Researchers gain new insight into how psychedelics affect the brain
Reuters · 6d ago
COMPASS Pathways (CMPS) Is Up 7.1% After FDA Priority Status For COMP360 Psilocybin Therapy
Simply Wall St · 05/05 01:37
Compass Pathways Price Target Announced at $18.00/Share by Jefferies
Dow Jones · 05/04 20:56
Compass Pathways Initiated at Buy by Jefferies
Dow Jones · 05/04 20:56
Jefferies Initiates Coverage On Compass Pathways with Buy Rating, Announces Price Target of $18
Benzinga · 05/04 20:46
Weekly Report: what happened at CMPS last week (0427-0501)?
Weekly Report · 05/04 09:14
Compass Pathways initiated with a Buy at Jefferies
TipRanks · 05/03 23:55
Buy Rating Backed by High Likelihood of COMP360 TRD Approval and Significant Upside from Conservative DCF Valuation
TipRanks · 05/03 23:45
A Look At Compass Pathways (CMPS) Valuation After Key FDA Priority Review Milestone
Simply Wall St · 05/03 06:33
Psychedelic: FDA awards Compass Pathways priority review voucher
TipRanks · 04/30 18:56
More
Webull provides a variety of real-time CMPS stock news. You can receive the latest news about Compass Pathways Plc through multiple platforms. This information may help you make smarter investment decisions.
About CMPS
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.